Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and/or female subjects between ≥18 and ≤75 years of age inclusive.
Diagnosis of moderate to severe active Lupus.
Receiving a stable dose of methotrexate, azathioprine, leflunomide, mizoribine, mycophenolate/mycophenolic acid, anti-malarials or corticosteroids.
You may not be if
Active renal lupus
Severe active central nervous system (CNS) lupus
Have cancer or a history of cancer within 5 years of screening.
Have a history of thrombosis (venous or arterial) or other vascular complications within the last 6 months, or any history of either recurrent thrombosis or a pulmonary embolus.
Active bacterial, viral, fungal, mycobacterial or other infections
Psychiatric condition including recent or active suicidal ideation or behavior
Have active fibromyalgia/myofascial/chronic pain.
Pregnant female subjects; breastfeeding female subjects; females subjects planning to become pregnant during the study; fertile male subjects and WOCBP who are unwilling or unable to use a highly effective method of contraception.
Clareo Health | A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
